Heart failure with reduced ejection fraction (HFrEF) remains a significant global health challenge, representing over half of all heart failure cases. To optimize patient outcomes, clinicians rely on HFrEF management guidelines to navigate complex diagnostic and therapeutic pathways. A recent systematic review published in European Heart Journal - Quality of Care and Clinical Outcomes examined twelve major guidelines to identify consensus areas and critical gaps in care.

The Four Pillars of Foundational Therapy

There is a strong international consensus regarding the pharmacological management of HFrEF. Modern guidelines consistently endorse the "four pillars" of medical therapy to improve survival and quality of life. These foundational treatments include renin-angiotensin-aldosterone system (RAAS) inhibitors—specifically sacubitril/valsartan (ARNI)—alongside beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors. Furthermore, experts emphasize early initiation and rapid titration of these agents to reduce mortality and hospitalization risk.

Consensus and Discord in HFrEF Management Guidelines

While the definition of HFrEF and initial diagnostic approaches are largely standardized, key differences persist across different regions. For instance, thresholds for serum natriuretic peptides vary significantly, which can impact early diagnosis in different clinical settings. Moreover, clinicians face conflicting advice regarding the sequencing of RAAS inhibitors and the specific indications for device-based therapies. These include implantable cardioverter-defibrillators (ICD) for non-ischaemic HFrEF and the optimal timing for cardiac resynchronization therapy (CRT).

Additionally, the review highlighted variability in the management of Stage A (at-risk) and Stage B (pre-heart failure) patients. Only a minority of the examined HFrEF management guidelines provided robust recommendations for managing common comorbidities. Addressing issues such as iron deficiency, atrial fibrillation, obesity, and sleep-disordered breathing is crucial for holistic patient care and preventing disease progression.

Looking Forward: The Need for Harmonization

The findings emphasize that although foundational care is well-defined, global harmonization is necessary to standardize advanced interventions and comorbidity management. Strengthening these guidelines will help clinicians deliver more consistent, high-quality care to HFrEF patients worldwide. Consequently, future updates should focus on resolving these discrepancies to optimize international clinical practice.

Frequently Asked Questions

What are the primary foundational therapies for HFrEF?

Current guidelines recommend four main classes: ARNI or RAAS inhibitors, evidence-based beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors.

Where do major HFrEF guidelines still differ?

Significant variability exists in natriuretic peptide thresholds, the specific sequencing of medications, and the indications for device therapies like ICDs in non-ischaemic cardiomyopathy.

Which comorbidities are often overlooked in standard guidelines?

Only a minority of guidelines provide detailed advice on managing iron deficiency, sleep-disordered breathing, frailty, and obesity in the context of heart failure.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Datta S et al. Heart failure with reduced ejection fraction: A systematic review of clinical practice guidelines and recommendations. Eur Heart J Qual Care Clin Outcomes. 2026 Mar 04. doi: undefined. PMID: 41778370.

Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421.

McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.